Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Timeline

Start

2021-03-05

Primary completion

2024-04-01

Completion

2024-04-01

Drugs

Indications